pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

107 catalysts · 25 phase 2 completion · 15 phase 1 completion · 13 phase 2 initiation · 13 phase 1 initiation · 10 patent expiry · 5 drug expiry

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-03: 32 catalysts2026-08-04: 13 catalysts2026-08-05: 18 catalysts2026-08-06: 11 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 2 catalysts2026-08-11: 1 catalyst2026-08-12: 2 catalysts2026-08-13: 1 catalyst2026-08-14: 1 catalyst2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 0 catalysts2026-10-27: 2 catalysts2026-10-28: 1 catalyst2026-10-29: 3 catalysts2026-10-30: 0 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: immunology×TA: infectious-disease×TA: dermatology×from 2017-01-04×clear all
type
  • phase 2 completion25
  • phase 1 completion15
  • phase 2 initiation13
  • phase 1 initiation13
  • patent expiry10
drug expiry
5
  • phase 3 initiation5
  • phase 0 trial completion4
  • phase 3 completion4
  • constraining patent expiry europe4
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    29
    ›Apr 24, 2026patent expiry102d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026patent expiry102d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026drug expiry102d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry102d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026phase 1 initiation102d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

    Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

    full page →CMSD-001 →source: globaldata
    ›Apr 24, 2026phase 1 results102d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

    Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

    full page →viral-specific T-cells →source: globaldata
    ›Apr 24, 2026phase 2 completion102d agoKothiwal Dental College and Research Centre — platelet rich plasma (Phase II Trial Completion)platelet rich plasma

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →platelet rich plasma →source: globaldata
    ›Apr 24, 2026phase 2 completion102d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

    Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

    full page →lixudebart →source: globaldata
    ›Apr 24, 2026phase 2 initiation102d agoSRM Kattankulathur Dental College and Hospital — human placental extract (Phase II Trial Initiation)human placental extract

    Therapy area: Dermatology. Indication: Wounds

    full page →human placental extract →source: globaldata
    ›Apr 24, 2026phase 3 completion102d agoBioClever 2005 SL — minoxidil (Phase III Trial Completion)minoxidil

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →minoxidil →source: globaldata
    ›Apr 24, 2026phase iv trial initiation102d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

    Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

    full page →melatonin →source: globaldata
    ›Apr 25, 2026phase 1 completion101d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

    Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

    full page →influenza (trivalent, split virion) vaccine →source: globaldata
    ›Apr 25, 2026phase 1 completion101d agoBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)YTS-109

    Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia

    full page →YTS-109 →source: globaldata
    ›Apr 25, 2026phase 2 completion101d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

    Therapy area: Infectious Disease. Indication: Dental Abscess

    full page →Gengigel →source: globaldata
    ›Apr 25, 2026phase 2 completion101d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

    full page →Himani fast relief gel →source: globaldata
    ›Apr 25, 2026phase 2 initiation101d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →dostarlimab →source: globaldata
    ›Apr 25, 2026phase 2 initiation101d agoKIMS Hospital — bifidobacterium (Phase II Trial Initiation)bifidobacterium

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →bifidobacterium →source: globaldata
    ›Apr 25, 2026phase 2 initiation101d agoGlenmark Pharmaceuticals Ltd — (clascoterone + latanoprost) (Phase II Trial Initiation)(clascoterone + latanoprost)

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →(clascoterone + latanoprost) →source: globaldata
    ›Apr 25, 2026phase 3 initiation101d agoDr. Reddy's Laboratories Ltd — olokizumab (Phase III Trial Initiation)olokizumab

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →olokizumab →source: globaldata
    ›Apr 26, 2026constraining patent expiry europe100d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Europe))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata
    ›Apr 26, 2026patent expiry100d agoBlue Blood Biotech Corp — BB-101 (Constraining Patent Expiry (Japan))BB-101

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →BB-101 →source: globaldata
    ›Apr 26, 2026phase 2 completion100d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

    Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

    full page →decidual stromal cells →source: globaldata
    ›Apr 26, 2026phase 2 completion100d agoChongqing Jinsaixing Medical Technology Co Ltd — Neauvia Intense (Phase II Trial Completion)Neauvia Intense

    Therapy area: Dermatology. Indication: Wrinkles

    full page →Neauvia Intense →source: globaldata
    ›Apr 26, 2026phase 2 completion100d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

    full page →bupivacaine →source: globaldata
    ›Apr 26, 2026phase 2 initiation100d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

    full page →DICLOFENAC SODIUM →source: globaldata
    ›Apr 26, 2026phase 2 initiation100d agoChittagong Medical College — difelikefalin (Phase II Trial Initiation)difelikefalin

    Therapy area: Dermatology, Genito Urinary System. Indication: Chronic Kidney Disease (Chronic Renal Failure), Pruritus

    full page →difelikefalin →source: globaldata
    ›Apr 26, 2026phase 3 completion100d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

    Therapy area: Infectious Disease. Indication: Rabies

    full page →rabies vaccine →source: globaldata
    ›Apr 26, 2026phase 3 initiation100d agoStanford University — zanubrutinib (Phase III Trial Initiation)zanubrutinib

    Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)

    full page →zanubrutinib →source: globaldata
    ›Apr 26, 2026phase iii iv trial completion100d agoRajaRajeswari Medical College & Hospital — stromal vascular fraction (Phase III/IV Trial Completion)stromal vascular fraction

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →stromal vascular fraction →source: globaldata

    Week of Apr 27, 2026

    21
    ›Apr 27, 2026phase 1 initiation99d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

    full page →pembrolizumab →source: globaldata
    ›Apr 27, 2026constraining patent expiry europe
    ← prev
    page 1 of 3
    next →
    99d ago
    Bill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Europe))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026patent expiry99d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026pdufa99d agoRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)dupilumab

    Therapy area: Dermatology. Indication: Chronic Urticaria

    full page →dupilumab →source: globaldata
    ›Apr 27, 2026phase 1 completion99d agoCTI Clinical Trial and Consulting Services Australia Pty Ltd — PTC-844 (Phase I Trial Completion)PTC-844

    Therapy area: Immunology. Indication: Unspecified Immunological Disorders

    full page →PTC-844 →source: globaldata
    ›Apr 27, 2026phase 1 completion99d agoFortrea Holdings Inc — balinatunfib (Phase I Trial Completion)balinatunfib

    Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis

    full page →balinatunfib →source: globaldata
    ›Apr 27, 2026phase 1 initiation99d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

    Therapy area: Immunology. Indication: Liver Transplant Rejection

    full page →fostamatinib →source: globaldata
    ›Apr 27, 2026phase 1 initiation99d agoBrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase I Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 2 completion99d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 initiation99d agoBrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase II Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 2 initiation99d agoNational Institute of Neurological Disorders and Stroke — brincidofovir (Phase II Trial Initiation)brincidofovir

    Therapy area: Infectious Disease. Indication: Progressive Multifocal Leukoencephalopathy

    full page →brincidofovir →source: globaldata
    ›Apr 27, 2026phase 2 3 initiation99d agoKLES Dr Prabhakar Kore Hospital & Medical Research Centre — esmolol (Phase II/III Trial Initiation)esmolol

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →esmolol →source: globaldata
    ›Apr 27, 2026phase 3 completion99d agoSanofi — meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) (Phase III Trial Completion)meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi)

    Therapy area: Infectious Disease. Indication: Neisseria meningitidis Infections

    full page →meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) →source: globaldata
    ›Apr 27, 2026phase 3 initiation99d agoSun Pharmaceutical Industries Ltd — ruxolitinib (Phase III Trial Initiation)ruxolitinib

    Therapy area: Dermatology. Indication: Vitiligo

    full page →ruxolitinib →source: globaldata
    ›Apr 27, 2026phase 3 initiation99d agoUniversity of Thessaly — abatacept (Phase III Trial Initiation)abatacept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →abatacept →source: globaldata
    ›Apr 27, 2026phase 3 initiation99d agoSiriraj Hospital — tranexamic acid (Phase III Trial Initiation)tranexamic acid

    Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism

    full page →tranexamic acid →source: globaldata
    ›Apr 27, 2026phase iv trial initiation99d agoAll India Institute of Medical Sciences Patna — typhoid Vi polysaccharide vaccine (Phase IV Trial Initiation)typhoid Vi polysaccharide vaccine

    Therapy area: Infectious Disease. Indication: Typhoid Fever

    full page →typhoid Vi polysaccharide vaccine →source: globaldata
    ›Apr 28, 2026constraining patent expiry europe98d agoLupin Ltd — (dolutegravir + lamivudine + tenofovir disoproxil fumarate) (Constraining Patent Expiry (Europe))(dolutegravir + lamivudine + tenofovir disoproxil fumarate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(dolutegravir + lamivudine + tenofovir disoproxil fumarate) →source: globaldata
    ›Apr 28, 2026patent expiry98d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →dolutegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry98d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata
    ›Apr 28, 2026patent expiry98d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    $GSK51.69-0.73%
    $SNY43.08+0.44%
    $GSK51.69-0.73%
    $FTRE19.17+0.47%
    $REGN762.63+3.29%
    $GSK51.69-0.73%
    $GSK51.69-0.73%